|Mr. Shaun Thaxter||CEO & Exec. Director||1.01M||N/A||N/A|
|Mr. Mark Crossley||CFO & Exec. Director||550.8k||N/A||N/A|
|Dr. Christian Heidbreder||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Ingo Elfering||Chief Information & Innovation Officer||N/A||N/A||N/A|
|Mr. Jason Thompson||VP of Investor Relations||N/A||N/A||N/A|
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior PLC’s ISS Governance QualityScore as of April 1, 2019 is 3. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 1; Compensation: 1.